Jiangsu Yao Yao Biotechnology

Jiangsu Yaoyao Biotechnology is a Chinese biotechnology company focused on the development of innovative metabolic and endocrine therapies. The company specializes in the research of multi-receptor agonists, particularly targeting GLP-1, GIP, and Glucagon receptors for the treatment of chronic conditions such as obesity and type 2 diabetes. Based in Jiangsu province, the firm leverages medicinal chemistry to design small molecule and peptide-based candidates with improved pharmacokinetic profiles. Yaoyao Biotech aims to address the growing global burden of metabolic diseases through high-efficiency drug discovery and development.